Clinical Trial Update: Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating bevacizumab with pelvic radiotherapy and primary chemotherapy in poor-risk rectal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Rectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-02-03